Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies

[1]  H. Sone,et al.  Patient‐based prediction algorithm of relapse after allo‐HSCT for acute Leukemia and its usefulness in the decision‐making process using a machine learning approach , 2019, Cancer medicine.

[2]  Yan-rong Liu,et al.  The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts , 2018, Bone Marrow Transplantation.

[3]  H. Dombret,et al.  Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia , 2018, Hematological oncology.

[4]  M. Labopin,et al.  Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT , 2018, Journal of Hematology & Oncology.

[5]  M. Norkin,et al.  Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia , 2017, Blood Cancer Journal.

[6]  Huiying Liang,et al.  Machine learning applications for prediction of relapse in childhood acute lymphoblastic leukemia , 2017, Scientific Reports.

[7]  M. Labopin,et al.  Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant , 2017, Haematologica.

[8]  P. Chevallier,et al.  Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation , 2016, Bone Marrow Transplantation.

[9]  L. Xu,et al.  Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT , 2014, Bone Marrow Transplantation.

[10]  A. Neubauer,et al.  Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis , 2014, Annals of Hematology.

[11]  M. Scholz,et al.  Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning , 2011, Leukemia.

[12]  A. Kiani,et al.  Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation , 2009, Haematologica.

[13]  R. Zini,et al.  Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia , 2009, Leukemia.

[14]  B. Brors,et al.  Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase , 2007, Leukemia.

[15]  M. Bernard,et al.  Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. , 2002, Blood.